Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
Vaccine ; 20 Suppl 5: B50-4, 2002 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-12477420

RESUMO

Influenza causes considerable morbidity and mortality and the damage to public health can be considerable. The most effective measures available for the prevention of influenza is vaccination. In most industrialised countries the objective of vaccination is to limit the disease among individuals at risk, especially the elderly. During the winter of 2000/2001, General Practitioners (GPs) monitored 14,818 elderly individuals. The objective was to evaluate the weekly incidence of the disease. Furthermore, we carried out a prospective study on 512 elderly individuals, arranged according to vaccination (304 vaccinated and 208 non-vaccinated), with the main objective of assessing the costs of the disease and the efficacy of vaccination. Finally, in order to assess the percentage of vaccinated elderly individuals, we carried out a telephone survey on 500 subjects. Our clinical surveillance study enabled us to establish that morbidity was particularly low in elderly individuals.The results of the prospective study allowed us to estimate the cost-benefit ratio at 8.22, with a net saving of 110.20 Euros for each vaccinated subject. We were also able to establish that the vaccine coverage among elderly individuals was 63%. Our study, though carried out during a low epidemic year, confirms the economic advantage of vaccination in the elderly.


Assuntos
Vacinas contra Influenza/economia , Influenza Humana/economia , Vacinação/economia , Idoso , Análise Custo-Benefício , Interpretação Estatística de Dados , Bases de Dados Factuais , Humanos , Incidência , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Entrevistas como Assunto , Itália/epidemiologia , Estudos Prospectivos , Fatores Socioeconômicos
4.
Dig Dis Sci ; 46(3): 524-9, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11318526

RESUMO

Damage to bile ducts in chronic hepatitis C is a characteristic histological lesion. Moreover, the presence of abnormal levels of gammaGT in these patients is also a common finding. Assessing whether the presence of bile duct lesions is indicated by biochemical abnormalities or whether virological characteristics can influence their development may help in the definition of clinical-histological relationships in chronic hepatitis C. In this study we evaluated the relationships among routine biochemical parameters, serum bile acids, and pi-class glutathione S-transferase levels, and the presence of bile duct lesions in 60 patients with chronic hepatitis C. Furthermore, we assessed whether the presence of bile duct lesion might be related to HCV genotype, HCV-RNA serum levels, and positivity for HGV-RNA. We found that gammaGT was the only parameter related to the presence of bile duct lesions. Although a trend towards higher serum bile acids and pi-class glutathione S-transferase levels was observed in patients with bile duct lesions, this trend did not reach statistical significance. Different HCV genotypes and RNA levels, and HGV-RNA positivity did not seem to influence the presence of bile duct damage. In conclusion we found that gammaGT levels point out the presence of bile duct lesions in patients with chronic hepatitis C. Since we observed a different pattern of alteration of gammaGT, serum bile acids, and pi-class glutathione S-transferase, we suggest that these various biochemical alterations reflect a more complex damage to bile duct structures, which is not likely represented by the common assessment of bile duct lesions. Viral factors such as HCV genotype and RNA levels as well as HGV-RNA positivity are probably not the main cause of this histological damage.


Assuntos
Ductos Biliares/patologia , Hepacivirus/genética , Hepatite C Crônica/sangue , Hepatite C Crônica/patologia , Hepatite Viral Humana/complicações , RNA Viral/sangue , gama-Glutamiltransferase/sangue , Adulto , Ácidos e Sais Biliares/sangue , Feminino , Flaviviridae/genética , Genótipo , Glutationa Transferase/sangue , Humanos , Masculino , Pessoa de Meia-Idade
5.
Am J Gastroenterol ; 95(11): 3211-7, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11095344

RESUMO

OBJECTIVE: The presence of steatosis is a common histological finding in patients with chronic hepatitis C (CHC). The causes of the severity of this condition are not yet clear, although both metabolic and viral factors supposedly are involved. In this study our aim was to examine the possible influence that leptin levels, hepatitis C virus (HCV) RNA levels, and hepatitis G virus (HGV) infection have on the severity of steatosis and on the presence and degree of fibrosis in patients with CHC. METHODS: One hundred eighty-two CHC patients with histological findings of steatosis were chosen from among a cohort of patients referred to our center for staging of liver disease. Among them 48 CHC patients were accurately selected so as to rule out possible confounding factors for the presence of steatosis (diabetes mellitus, hyperlipemia, obesity, alcohol). Leptin levels, HCV RNA levels, and HCV genotype, and the presence of HGV RNA were assessed in these patients and related to histological findings. RESULTS: We found that leptin levels in CHC patients were similar to those in healthy subjects. No relationship was found between leptin levels and severity of steatosis. HCV RNA levels, HCV genotype, and the presence of HGV infection were no different among CHC patients with various degrees of steatosis. Leptin was not related to different degrees of fibrosis, whereas higher viral load was the only parameter associated to higher fibrosis scores. CONCLUSIONS: These findings suggest that the degree of steatosis in patients with CHC does not seem to depend on serum leptin levels or on viral factors, at least as far as HCV viremia and genotype and HGV infection are concerned. The severity of fibrosis does not seem to be influenced by leptin levels, whereas HCV viral load does seem to play some role.


Assuntos
Fígado Gorduroso/patologia , Hepatite C Crônica/patologia , Leptina/sangue , Cirrose Hepática/patologia , Fígado/patologia , Adulto , Estudos de Casos e Controles , Feminino , Flaviviridae/genética , Hepacivirus/isolamento & purificação , Hepatite C Crônica/sangue , Hepatite Viral Humana/patologia , Humanos , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Índice de Gravidade de Doença , Carga Viral
6.
Funct Neurol ; 15(2): 81-6, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10916719

RESUMO

The aims of this study were to assess autonomic nervous function in subjects with recently diagnosed Parkinson's disease (de novo patients) and to evaluate its changes following acute levodopa administration. In 13 patients (8 males, 5 females) and 13 age-matched control subjects, three cardiovascular autonomic function tests (Deep Breathing, Valsalva, Lying to Standing) were performed, the QT interval was calculated on a 12-lead electrocardiogram, and the response of plasma norepinephrine to standing was assessed in basal conditions. The cardiovascular tests and the measurement of the QT interval were repeated in de novo Parkinsonian patients 90 minutes after the administration of levodopa 200 mg per os. The results of the Deep Breathing and Valsalva tests were worse and the QT interval longer in patients than in control subjects (although the differences were not statistically significant). The heart rate increase at 30 seconds after standing up was significantly higher in Parkinsonian patients than in the control group. The response of plasma norepinephrine to standing was similar in both groups. Levodopa administration produced a slight improvement in the Deep Breathing test, a shortening of the QT interval and increased tachycardia on standing. Our data suggest that a mild subclinical impairment of parasympathetic function can be a feature of de novo Parkinsonian patients and that levodopa therapy could have a beneficial effect on this autonomic dysfunction.


Assuntos
Antiparkinsonianos/uso terapêutico , Frequência Cardíaca/fisiologia , Hipertensão/diagnóstico , Levodopa/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Adulto , Idoso , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Cromatografia Líquida de Alta Pressão , Esquema de Medicação , Feminino , Testes de Função Cardíaca , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/fisiopatologia , Levodopa/administração & dosagem , Levodopa/farmacologia , Síndrome do QT Longo/complicações , Síndrome do QT Longo/diagnóstico , Masculino , Pessoa de Meia-Idade , Norepinefrina/sangue , Doença de Parkinson/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...